MX2022009170A - Methods for treatment of cancer with an anti-tigit antagonist antibody. - Google Patents
Methods for treatment of cancer with an anti-tigit antagonist antibody.Info
- Publication number
- MX2022009170A MX2022009170A MX2022009170A MX2022009170A MX2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A MX 2022009170 A MX2022009170 A MX 2022009170A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- treatment
- antagonist antibody
- tigit antagonist
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Abstract
The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
Applications Claiming Priority (15)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062966448P | 2020-01-27 | 2020-01-27 | |
US202062985822P | 2020-03-05 | 2020-03-05 | |
US202062994272P | 2020-03-24 | 2020-03-24 | |
PCT/US2020/024526 WO2021194481A1 (en) | 2020-03-24 | 2020-03-24 | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US202063059054P | 2020-07-30 | 2020-07-30 | |
US202063059960P | 2020-07-31 | 2020-07-31 | |
US202063074827P | 2020-09-04 | 2020-09-04 | |
US202063074807P | 2020-09-04 | 2020-09-04 | |
PCT/US2020/049415 WO2022050954A1 (en) | 2020-09-04 | 2020-09-04 | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
US202063085890P | 2020-09-30 | 2020-09-30 | |
US202063105198P | 2020-10-23 | 2020-10-23 | |
US202063114517P | 2020-11-16 | 2020-11-16 | |
US202063124693P | 2020-12-11 | 2020-12-11 | |
US202063127109P | 2020-12-17 | 2020-12-17 | |
PCT/US2021/015143 WO2021154761A1 (en) | 2020-01-27 | 2021-01-26 | Methods for treatment of cancer with an anti-tigit antagonist antibody |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009170A true MX2022009170A (en) | 2022-08-17 |
Family
ID=74626264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022009170A MX2022009170A (en) | 2020-01-27 | 2021-01-26 | Methods for treatment of cancer with an anti-tigit antagonist antibody. |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4096646A1 (en) |
JP (1) | JP2023511595A (en) |
KR (1) | KR20220133243A (en) |
CN (1) | CN115315256A (en) |
AU (1) | AU2021212662A1 (en) |
CA (1) | CA3165187A1 (en) |
IL (1) | IL294800A (en) |
MX (1) | MX2022009170A (en) |
TW (1) | TW202142230A (en) |
WO (1) | WO2021154761A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230025691A (en) * | 2020-06-16 | 2023-02-22 | 제넨테크, 인크. | Methods and compositions for treating triple negative breast cancer |
BR112023026966A2 (en) * | 2021-07-02 | 2024-03-12 | Hoffmann La Roche | METHODS FOR TREATING AN INDIVIDUAL WITH MELANOMA, FOR ACHIEVING A CLINICAL RESPONSE, FOR TREATING AN INDIVIDUAL WITH NON-HODGKIN LYMPHOMA, FOR TREATING A POPULATION OF INDIVIDUALS WITH NON-HODGKIN LYMPHOMA, AND FOR TREATING AN INDIVIDUAL WITH METASTATIC COLORECTAL CANCER |
WO2023010094A2 (en) * | 2021-07-28 | 2023-02-02 | Genentech, Inc. | Methods and compositions for treating cancer |
KR20240047393A (en) * | 2021-08-10 | 2024-04-12 | 머크 샤프 앤드 돔 엘엘씨 | A therapeutic combination comprising a TIGIT antagonist, a PD-1 antagonist and a chemotherapy agent(s) |
WO2023018675A1 (en) * | 2021-08-10 | 2023-02-16 | Merck Sharp & Dohme Llc | A therapeutic combination comprising a tigit antagonist, a pd-1 antagonist, and lenvatinib |
WO2023040804A1 (en) * | 2021-09-14 | 2023-03-23 | 信达生物制药(苏州)有限公司 | Pharmaceutical composition of anti-pd-1 antibody and chemotherapy agent and method for using same |
TW202328195A (en) * | 2021-09-15 | 2023-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Proteins that specifically bind to pd-1 and the pharmaceutical use thereof |
WO2023122665A1 (en) * | 2021-12-22 | 2023-06-29 | Genentech, Inc. | Clinical formulations of anti-tigit antibodies |
CN114181310B (en) * | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | anti-TIGIT antibody, and pharmaceutical composition and use thereof |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
JPH07501451A (en) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | Multivalent antigen binding protein |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9314893D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Quinazoline derivatives |
IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
BR9508409A (en) | 1994-07-21 | 1997-12-23 | Akzo Nobel Nv | Storage stable transportable peroxide composition and use of an organic peroxide formulation |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
EP2295415A1 (en) | 1995-03-30 | 2011-03-16 | OSI Pharmaceuticals, Inc. | Quinazoline derivatives |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
GB9508565D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quiazoline derivative |
US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
SI9620103A (en) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
PL190489B1 (en) | 1996-04-12 | 2005-12-30 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ES2186908T3 (en) | 1996-07-13 | 2003-05-16 | Glaxo Group Ltd | HETEROCICICLES CONDENSED COMPOUNDS AS INHIBITORS OF PPROTEINA-TIROSINA-QUINASAS. |
ID18494A (en) | 1996-10-02 | 1998-04-16 | Novartis Ag | PIRAZOLA DISTRIBUTION IN THE SEQUENCE AND THE PROCESS OF MAKING IT |
UA73073C2 (en) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Substituted 3-cyan chinolines |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
WO1998050038A1 (en) | 1997-05-06 | 1998-11-12 | American Cyanamid Company | Use of quinazoline compounds for the treatment of polycystic kidney disease |
ZA986729B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitors of tyrosine kinases |
ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
KR20010031813A (en) | 1997-11-06 | 2001-04-16 | 윌리암 에이취 캘넌, 에곤 이 버그 | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
ATE531812T1 (en) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | HUMANIZATION OF RODENT ANTIBODIES |
ES2188254T3 (en) | 1998-11-19 | 2003-06-16 | Warner Lambert Co | N- (4- (3-CHLORO-4-FLUORO-PHENYLAMINE) -7- (3-MORFOLIN-4-IL-PROPOXI) -QUIN AZOLIN-6-IL) -ACRILAMADA, AN IRREVERSIBLE THYROSINE KINASE INHIBITOR. |
EP2592155B2 (en) | 2004-06-04 | 2019-09-11 | Genentech, Inc. | EGFR mutations |
EP2898329B1 (en) | 2012-09-24 | 2017-05-17 | Ventana Medical Systems, Inc. | Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker |
ES2835866T3 (en) | 2015-05-12 | 2021-06-23 | Hoffmann La Roche | Therapeutic and diagnostic procedures for cancer |
KR20180012753A (en) | 2015-05-29 | 2018-02-06 | 제넨테크, 인크. | Treatment and Diagnosis Methods for Cancer |
WO2019165434A1 (en) * | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
-
2021
- 2021-01-26 AU AU2021212662A patent/AU2021212662A1/en active Pending
- 2021-01-26 CA CA3165187A patent/CA3165187A1/en active Pending
- 2021-01-26 KR KR1020227029306A patent/KR20220133243A/en unknown
- 2021-01-26 CN CN202180022830.2A patent/CN115315256A/en active Pending
- 2021-01-26 JP JP2022545057A patent/JP2023511595A/en active Pending
- 2021-01-26 WO PCT/US2021/015143 patent/WO2021154761A1/en unknown
- 2021-01-26 TW TW110102913A patent/TW202142230A/en unknown
- 2021-01-26 EP EP21705841.1A patent/EP4096646A1/en active Pending
- 2021-01-26 MX MX2022009170A patent/MX2022009170A/en unknown
- 2021-01-26 IL IL294800A patent/IL294800A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20220133243A (en) | 2022-10-04 |
CA3165187A1 (en) | 2021-08-05 |
EP4096646A1 (en) | 2022-12-07 |
IL294800A (en) | 2022-09-01 |
TW202142230A (en) | 2021-11-16 |
JP2023511595A (en) | 2023-03-20 |
WO2021154761A1 (en) | 2021-08-05 |
AU2021212662A1 (en) | 2022-08-11 |
CN115315256A (en) | 2022-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009170A (en) | Methods for treatment of cancer with an anti-tigit antagonist antibody. | |
CY1120300T1 (en) | CLAUDIN 6 SPECIALTY PARTS (CLDN6) | |
CY1117031T1 (en) | CLAUDIN-18 Monoclonal Antibodies In Cancer Treatment | |
MX2021014096A (en) | Heterocyclic compounds, preparation methods and uses thereof. | |
MX2020012204A (en) | Kras g12c inhibitors for treating cancer. | |
MX2020012261A (en) | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer. | |
MX2019009967A (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof. | |
JOP20170131B1 (en) | 1-trahydropyranylcarbonyl-2,3-dihydro-1h-indole compounds for treating cancer | |
CY1121085T1 (en) | ANTIBODIES FOR TREATMENT OF CANCER EXPRESSING CLAUDINE 6 | |
MX2020012797A (en) | Anti-pvrig/anti-tigit bispecific antibodies and methods of use. | |
CA3156451A1 (en) | Antibodies having specificity for nectin-4 and uses thereof | |
MY163024A (en) | Therapy of platinum-resistan cancer | |
MX2020008882A (en) | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies. | |
MX2008015498A (en) | Treatment of metastatic breast cancer. | |
EA024630B9 (en) | Pyrazole derivatives as calcium release-activated calcium (crac) channel inhibitors | |
NZ628298A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
PE20080663A1 (en) | TUMOR THERAPY WITH A COMBINATION OF ANTI-HER2 ANTIBODIES | |
MX2009009816A (en) | Monoclonal antibodies for treatment of cancer. | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
MX2020008613A (en) | Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer. | |
PE20221830A1 (en) | SPECIFIC ANTIBODIES AGAINST CLAUDIN 18.2 TUMOR | |
MX2021005784A (en) | Compounds that selectively and effectively inhibit hakai-mediated ubiquitination, as anti-cancer drugs. | |
MX2018001095A (en) | Treatment of patients diagnosed with pancreatic ductal adenocarcinoma using using monoclonal antibodies against the epidermal growth factor receptor (egfr). | |
WO2023081637A8 (en) | Fused tetracyclic quinazoline derivatives as inhibitors of erbb2 | |
BG108932A (en) | Pharmaceutical composition comprising arsenite for the treatment of malignancy |